Molecular Partners AG
MOLNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Apr 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 16, 2026 |
| JP Morgan | maintain | Neutral | Dec 8, 2025 |
| JP Morgan | maintain | Neutral | Sep 3, 2025 |
| JP Morgan | maintain | Neutral | Dec 5, 2023 |
| SVB Leerink | downgrade | Outperform →Market Perform | Aug 29, 2022 |
| Credit Suisse | upgrade | Underperform →Neutral | May 25, 2022 |
| SVB Leerink | maintain | Outperform | Apr 27, 2022 |
| SVB Leerink | maintain | Outperform | Jan 14, 2022 |
| SVB Leerink | maintain | Outperform | Aug 27, 2021 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.44| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 29, 2026 | $-0.38 | $-0.46 | — | — |
| Aug 25, 2026 | $-0.44 | $-0.45 | — | — |
| May 12, 2026 | $-0.45 | $-0.38 | — | — |
| Mar 12, 2026 | $-0.41 | $-0.40 | — | — |
| Oct 30, 2025 | $-0.41 | $-0.46 | — | — |
| Aug 25, 2025 | $-0.67 | $-0.53 | — | — |
| May 15, 2025 | $-0.50 | $-0.42 | — | — |
| Mar 6, 2025 | $-0.34 | $-0.44 | — | — |
News
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data supporting an attractive therapeutic window for MP0632, a logic-gated Switch-DARPin T cell engager (TCE) with integrated CD2 co-stimulation, at the Society for Immunotherapy o…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold presentations on its lead Radio-DARPin candidate MP0712, co-developed with Orano Med, at two upcoming scientific conferences, including the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) …
The heavy selling pressure might have exhausted for Molecular Partners AG Sponsored ADR (MOLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics, (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the third quarter of 2026, as well as a deepened focus on radiopharmaceuticals and streamlining of its resources.
Molecular Partners (NASDAQ: MOLN - Get Free Report) and Coherus Oncology (NASDAQ: CHRS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Molecular
Vertex Pharmaceuticals (NASDAQ: VRTX - Get Free Report) and Molecular Partners (NASDAQ: MOLN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends. Analyst Recommendations This is a summary of recent
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today reported corporate highlights and financial results for the first half of 2026.